Atlas Trials

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Clinical trial NCT01605227 · COMPLETED

Trial details

NCT number
NCT01605227
Sponsor
Exelixis
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Prostate CancerCastration Resistant Prostate CancerPainProstatic Neoplasms
Start date
2012-07-01
Primary completion
2014-09-01
Enrollment
1028

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.